LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

TransMedics Group Inc

Chiusa

SettoreSettore sanitario

114.92 -0.72

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

110.43

Massimo

115.8

Metriche Chiave

By Trading Economics

Entrata

-11M

24M

Vendite

-14M

144M

P/E

Media del settore

47.996

105.69

Margine di Profitto

16.909

Dipendenti

728

EBITDA

-13M

33M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+24.34% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-333M

4.2B

Apertura precedente

115.64

Chiusura precedente

114.92

Notizie sul Sentiment di mercato

By Acuity

50%

50%

185 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

TransMedics Group Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 ago 2025, 19:15 UTC

I principali Market Mover

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Confronto tra pari

Modifica del prezzo

TransMedics Group Inc Previsione

Obiettivo di Prezzo

By TipRanks

24.34% in crescita

Previsioni per 12 mesi

Media 143.67 USD  24.34%

Alto 170 USD

Basso 115 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TransMedics Group Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

8

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

92.43 / 94.18Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Weak Bullish Evidence

Sentiment

By Acuity

185 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat